A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Idiopathic pulmonary fibrosis; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms J-SONIC

03 Oct 2022 Status changed from active, no longer recruiting to completed.
31 Mar 2022 Primary endpoint (Time to acute exacerbation of IPF (Initiation of 2nd line chemotherapy for non-small cell lung cancer is not treated as censored) has not been met according to the resultsal .
31 Mar 2022 Results assessing safety and efficacy of nintedanib plus chemotherapy (experimental arm) compared with chemotherapy alone for advanced non-small cell lung cancer with IPF published in the European Respiratory Journal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com